Ali Rezaie, MD, is medical director of the GI Motility Program at Cedars-Sinai.

New Study Raises Safety Concerns for Antidepressant Use in IBS

Management of irritable bowel syndrome (IBS) has undergone a notable evolution in recent decades, shifting from largely empirical, symptom-based treatment toward a more nuanced, mechanism-driven approach. However, as clinicians increasingly rely on long-term pharmacotherapy for a condition often diagnosed in early adulthood, questions around the durability and safety of these treatments have come into sharper focus.

A recent large-scale study led by Ali Rezaie, MD, medical director of the GI Motility Program at Cedars-Sinai, sought to address a critical gap in the literature surrounding the long-term mortality risk associated with commonly used IBS medications. His research utilized nearly 2 decades of electronic health records from > 650,000 US adults with IBS, making it the largest real-world study to examine the long-term safety of IBS treatments.

“One important thing about the irritable bowel syndrome is that a lot of patients are diagnosed in their 20s, 30s, or 40s. If you start them on a medication, this is not necessarily a curable disease, so they will be on that medication for years and decades,” Rezaie explained. “The issue is that when we do clinical trials using medications, they have a limited timeframe and they're generally small, so a rare side effect or long-term side effects will not pop up in those types of research. It's very important when we are treating patients with a specific medication to know whether there are risks associated with it.”

He and colleagues performed a retrospective cohort study using a nationwide US electronic health record database from January 2005 to January 2023. Their 1:1 propensity score-matched cohort included 669,083 adults with IBS. Patients were grouped by pharmacotherapy use, with subgroup analyses for IBS with diarrhea (IBS-D) and IBS with constipation (IBS-C). Rezaie noted the analysis accounted for more than 50 variables—including comorbidities, concomitant medications, demographics, and lifestyle factors—to minimize confounding.

Results showed antidepressant use was associated with an increased risk of all-cause mortality (hazard ratio [HR], 1.35; 95% CI, 1.26–1.45; mortality rate, 1.6% vs 1.0%) and remained consistent across antidepressant subclasses and demographic subgroups.

While the relative increase was approximately 30%, the absolute risk difference remained modest. However, given that IBS affects a substantial portion of the US population, Rezaie noted that even small absolute increases could translate into meaningful population-level impact.

“Individually, the risk is not that high, but if you think about the fact that more than 10% of the US population has irritable bowel syndrome, that 0.6% potentially can translate into a significant number of deaths that we can potentially induce by starting patients on antidepressants in an IBS, which is not a fatal disease by itself,” he explained.

Further analyses reinforced the robustness of these findings. Comparisons with active comparator groups, stratification by age, and evaluation of negative control conditions all supported the observed association. Additionally, a dose-response relationship emerged, with higher numbers of prescription refills correlating with greater mortality risk. Mechanistically, the study identified increased rates of known antidepressant-related adverse events, including falls, arrhythmias, heart failure, bleeding, and suicidal ideation, which may mediate this risk.

Of note, results additionally showed antispasmodic use was not linked to increased mortality (HR, 0.95; 95% CI, 0.89–1.00).

Subgroup analyses provided additional clinical insight. For IBS-D, cholestyramine/colestipol, eluxadoline, and rifaximin were not associated with mortality. However, diphenoxylate (HR, 1.89; 95% CI, 1.02–3.51) and loperamide (HR, 2.39; 95% CI, 1.48–3.90) show increased mortality risk. For IBS-C, polyethylene glycol-3350 and secretagogues showed no significant association with mortality.

Rezaie emphasized the implications for clinical practice. Because IBS is a chronic, non-fatal condition often requiring decades of management, long-term safety data are essential for informed decision-making. He noted that current guidelines largely lack such data and continue to emphasize symptom control without fully addressing potential long-term harms. These findings, he suggested, should prompt more transparent discussions with patients and may ultimately inform future guideline updates.

“I guess the bottom line is that when we are starting patients on medications for irritable bowel syndrome, along with the safety data that we have from clinical trials, I think it's fair to describe the long term side effects of these medications with the patients for more informed decision making,” he said “Also, I think right now, societal guidelines are are not incorporating long term side effects because there's no data, and hopefully this [research] will guide some of those recommendations and societal guidelines.”

Editors’ note: Rezaie reports relevant disclosures with Bausch Health, Ardelyx, and others.

 Association of pharmacotherapy with all-cause mortality among patients with irritable bowel syndrome. 

https://doi.org/10.1038/s43856-026-01498-6

Cedars-Sinai Medical Center. Some common IBS treatments linked to higher risk of death. EurekAlert! April 8, 2026. Accessed April 9, 2026. 

https://www.eurekalert.org/news-releases/1122913

Videos

New long-term data link antidepressant use in IBS to higher mortality risk. Rezaie explains key findings and clinical implications.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Are We Overlooking Long-Term Risks in IBS Management? New 20-Year Safety Data, With Ali Rezaie, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Despite being a relatively quiet first quarter in terms of approvals from the 

, cardiology had no shortage of groundbreaking developments over the first 3 months of 2026. Between major trial results and substantial overhauling of guidelines, everything from 

 and myocardial infarction saw significant advancements. Additionally, the American College of Cardiology (ACC) Scientific Sessions 2026, conducted in New Orleans, Louisiana, from March 28-30, brought with it a tremendous amount of news across a plethora of specialties.

With so much news coming out of the start of the year, the editorial team at 

 has put together a collection of the most impactful headlines from January to March of 2026. Catch up with any news you may have missed below:

OCEANIC-STROKE: Asundexian Reduces Stroke Risk Without Increasing Bleeding, With Andrew Russman, DO


OCEANIC-STROKE concluded in February of 2026, indicating the superiority of asundexian to placebo in preventing 

 in patients after non-cardioembolic ischemic stroke or high-risk transient ischemic attack. A total of 12,327 patients were enrolled in the trial – among these patients, the team noted that asundexian reduced ischemic stroke by 26% with no increase in risk of ISTH major bleeding. This finding was consistent across all subgroups. Additionally, secondary endpoints highlighted asundexian’s beneficial effect on ischemic and hemorrhagic stroke with no major increase in the ISTH major bleeding rate.


RSV Vaccine Demonstrates Cardioprotective Effects, Reduces MACE and Hospitalizations, With Deepak Bhatt, MD, MPH


In February of 2026, GSK published a study investigating its Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted – marketed under the name Arexvy – to display its efficacy in reducing major adverse cardiovascular events and RSV-related hospitalizations in adults over 60. The retrospective cohort study was presented at RSVVW’26, the 9th Conference of the Respiratory Syncytial Virus Foundation, and enrolled a total of 520,440 patients. The vaccine demonstrated 20.4% effectiveness in patients with existing cardiovascular disease, demonstrating its substantial benefit in preventing RSV-related cardiovascular events.


CORALreef Lipids: Enlicitide Reduces LDL-C in Patients With ASCVD, With Ann Marie Navar, MD, PhD


The final data from CORALreef Lipids were presented in February of 2026, displaying enlicitide decanoate’s efficacy in lowering LDL-C versus placebo in patients with a major 

atherosclerotic cardiovascular disease (ASCVD)

 event. Patients across both the treatment and placebo arms displayed substantial treatment adherence across the full 52 weeks, inspiring hope among the participating investigators that the comparative simplicity of oral enlicitide will overcome prescription inertia in dyslipidemia management.


ADA’s Obesity Association Releases Guidelines for Use of Obesity Medications


On January 13, 2026, the Obesity Association, a subdivision of the American Diabetes Association, published a new section in the 

Standards of Care in Overweight and Obesity

, discussing pharmacotherapy’s updated role in reducing weight and improving outcomes. The document spotlights weight-promoting medications for major disorders such as diabetes and 

, positing alternatives to avoid excess weight gain and thereby avert cardiovascular damage. Additionally, the writers emphasized the importance of intensive behavioral therapy.

Updated ACC/AHA Dyslipidemia Guidelines Incorporate LDL-C Goals, Lp(a) Focus, With Deepak Bhatt, MD, MPH


On March 13, 2026, the ACC and the American Heart Association (AHA) released an updated clinical guideline for the management of dyslipidemia. The document replaced the 2018 guidelines on blood cholesterol management. The new document emphasizes the testing of Lp(a) levels as a COR I suggestion, as well as reinstating targeted LDL-C goals after years of percent LDL-C reductions to monitor patient progress. These goals are assigned based on the PREVENT risk calculator.


New Pulmonary Embolism Guidelines Highlight Progress, Encourage Research, With Mark Creager, MD


Published on February 19, 2026, the ACC and AHA put out a clinical practice guideline for acute pulmonary embolism (PE) treatment, representing the first ever published from these institutions. The guide includes a new classification scheme of 5 categories, equivalent to low to high risk of adverse outcomes. The document also encourages the use of direct oral anticoagulant medications over vitamin K antagonists in eligible patients.


Evolocumab Reduces CV Risk in Non-Atherosclerotic Patients With Diabetes, With Nicholas Marston, MD, MPH


A secondary analysis of the VESALIUS-CV trial, presented at ACC.26, has revealed evolocumab’s capacity to reduce the risk of first major adverse cardiovascular events in patients with diabetes but no known significant atherosclerosis. The analysis incorporated a composite primary endpoint of coronary heart disease death, myocardial infarction, or ischemic stroke (3-P MACE), while another included ischemia-driven arterial revascularization on top of the previous 3. Ultimately, 3-P MACE occurred in 83 patients in the treatment arm compared to 117 in placebo, while 4-P MACE occurred in 127 in the treatment arm and 178 in the placebo arm.


LV Unloading Before Delayed PCI Reduces Infarct Size by 1%, With Gregg Stone, MD, and Navin Kapur, MD


The STEMI-Door to Unload (DTU) study may not have achieved statistical significance, but a 1% reduction in infarct size after left ventricular unloading and a 30-minute delay prior to percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI) presents a promising path for future research. Presented at ACC.26, this trial demonstrates a significant opportunity for the therapy moving forward, as the device not increasing infarct size establishes its safety, if not its efficacy.

CHAMPION-AF: Left Atrial Appendage Closure Noninferior to NOACs


Device-based left atrial appendage closure (LAAC) was noninferior to non-vitamin K antagonist oral anticoagulant (NOAC) therapy for the prevention of adverse events in patients with 

, according to results from the CHAMPION-HF trial. Patients were given either the Watchman FIx device or an approved NOAC, after which they were administered short-term antithrombotic therapy for 3 months before transitioning to antiplatelet therapy. At 3 years, the primary endpoint – a composite of cardiovascular death, stroke, or systemic embolism, occurred in 81 patients in the device group and 65 patients in the NOAC group, yielding a difference of 0.9%.

Articles

Cardiology’s early-2026 landscape featured pivotal trial readouts, new pharmacotherapy guidance, and major ACC/AHA guideline revisions, alongside high-impact data from ACC.26. Factor XIa inhibition with asundexian reduced recurrent ischemic stroke without excess major bleeding, while RSV vaccination showed meaningful cardiovascular event mitigation in older adults. Novel lipid-lowering strategies advanced, including oral enlicitide and expanded PCSK9 benefit signals. Guideline changes emphasized obesity pharmacotherapy, renewed LDL-C targets, routine Lp(a) testing, and a first ACC/AHA acute PE framework favoring DOACs.

Catch up on major trial results, groundbreaking guideline updates, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Atherosclerotic Cardiovascular Disease

Arrhythmia

Dyslipidemia

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

Structural Heart Disease

Cardiomyopathy

Venous Thromboembolism

The HCPLive venous thromboembolism page is a resource for medical news and expert insights on VTE. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for thrombotic disease, and more.

Strategic Alliance Partnership

Q1 2026 Recap: Cardiology News and Updates

Simon Davies, MD, is  a consultant nephrologist at the University Hospital of North Midlands and Professor of Nephrology and Dialysis Medicine, as well as director of the Institute for Applied Clinical Sciences at Keele University.

Gaps in Home Dialysis Access Persist Globally, With Simon Davies, MD

The global gaps in access and adoption of home dialysis persist despite previously established clinical and quality-of-life benefits. 

The International Home Dialysis Consortium (IHDC) has worked to identify how system-level barriers, provider biases, and policy misalignment continue to limit home dialysis implementation across the world.

At the World Congress of Nephrology (WCN) in Yokohama, Japan, Simon Davies, MD, a consultant nephrologist at the University Hospital of North Midlands and Professor of Nephrology and Dialysis Medicine, as well as director of the Institute for Applied Clinical Sciences at Keele University, presented findings from IHDC and discussed them in an interview with HCPLive.

Home dialysis, including peritoneal dialysis (PD) and home hemodialysis (HHD), has long been associated with improved quality of life, greater patient autonomy, and lower overall healthcare costs compared with in-center hemodialysis. Despite these advantages, its use remains highly variable across regions and is often limited by disparities in access, education, infrastructure, and policy. In many settings, particularly in low- and middle-income countries, home dialysis remains underutilized or unavailable, while even high-income countries continue to demonstrate inconsistent adoption across centers.

“I often use the analogy of an onion—you peel away layers of barriers, and even as you get deeper, there are still barriers tied to underlying biases and conditions. These can include a lack of education or understanding of how to deliver the therapy, leading to an understandable reluctance to use it,” explained Davies. “Even when those barriers are removed—for example, in the UK, where financial barriers are not a factor, and everyone should be trained in PD—there is still considerable variation between dialysis centers. That variation seems to reflect differences in belief in the therapy and the culture around ensuring patients are informed about and able to engage with all available options.”

Davies emphasized that these gaps are not solely driven by patient-level factors, but are deeply rooted in how health systems are structured. Differences in reimbursement models, provider incentives, and institutional priorities can all influence whether home dialysis is presented as a viable option to patients.

“I think the really big barriers are how health systems are set up. Wherever somebody makes more money from one therapy rather than another, it’s not a level playing field—and that varies quite a lot from country to country,” Davies said. “If it’s not a level playing field financially for providers, then it’s very hard to make the case for home dialysis.”

Beyond financial considerations, he noted that clinician comfort and perception continue to shape modality selection. Persistent biases and limited familiarity with home-based therapies may lead providers to default to in-center options, even when home dialysis could be appropriate.

“There are still biases present which need to be addressed, and people will use any excuse not to do it if they’re not comfortable with the therapy or think it’s not the right thing for their patients,” Davies added.

The IHDC, a relatively new global initiative, aims to address these multifaceted barriers through collaboration across clinicians, policymakers, and industry stakeholders. By creating a shared framework and offering practical resources, the consortium seeks to support regions working to expand access to home dialysis.

“If you can change policy by creating an environment that encourages the use of home dialysis, there are various levers you can bring in—usually financial—that can make that happen,” Davies said. “Having a group with shared experience and expertise makes it much easier to have those conversations with policymakers.”

Through these efforts, IHDC aims to reduce global disparities in dialysis care and promote more equitable access to home-based treatment options.

Brown EA, Jha V, Bavanandan S, et al. International Home Dialysis Consortium: Declaration Advocating for the Promotion of Home Dialysis Globally. 

https://doi.org/10.1016/j.ekir.2025.03.012

Palmer SC, Palmer AR, Craig JC, et al. Home versus in-centre haemodialysis for end-stage kidney disease. 

. Published online November 20, 2014. doi:

https://doi.org/10.1002/14651858.cd009535.pub2

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Chronic Kidney Disease

How Envudeucitinib May Fit Into the Evolving Oral Psoriasis Landscape, With Andrew Blauvelt, MD, MBA

2026 American Academy of Dermatology (AAD) Annual Meeting

 held in Denver, Colorado, from March 27-31, marked a watershed moment for the oral psoriasis treatment landscape, with late-breaking phase 3 data presented for 2 next-generation TYK2 inhibitors — envudeucitinib and zasocitinib — arriving just weeks after the FDA approval of icotrokinra (Icotyde), the first oral IL-23 receptor antagonist approved for moderate to severe plaque psoriasis. Andrew Blauvelt, MD, MBA, owner of Blauvelt Consulting, in Annapolis, Maryland, and a principal investigator on the ONWARD program, spoke about where envudeucitinib fits in the context of this rapidly expanding field. 

Blauvelt characterized envudeucitinib as a second-generation TYK2 inhibitor specifically engineered for complete 24-hour target coverage — distinct from the first approved agent in the class, deucravacitinib — and the only TYK2 inhibitor to date shown to achieve maximal inhibition over a full dosing interval in humans. The ONWARD1 and ONWARD2 trials together enrolled more than 1,700 adults with moderate to severe plaque psoriasis, randomized 2:1:1 to envudeucitinib 40 mg twice daily, placebo, or the active comparator apremilast, with co-primary endpoints of PASI 75 and static Physician's Global Assessment (sPGA) 0/1 at week 16. Both studies met all primary and secondary endpoints with high statistical significance versus placebo (

 <.0001). At week 16, approximately 74% to 75% of envudeucitinib-treated patients achieved PASI 75 and 59% achieved sPGA 0/1. Response continued to deepen through week 24, at which point approximately 80% achieved PASI 75, approximately 65% achieved PASI 90, and more than 40% achieved PASI 100 — complete skin clearance. Envudeucitinib outperformed apremilast on all PASI endpoints at week 24 (

 <.0001), with separation from placebo on PASI 90 observed as early as week 4. The safety profile was favorable and consistent with phase 2 findings, with nasopharyngitis and upper respiratory tract infection the most common adverse events and notably no lipid signal of the type observed in earlier deucravacitinib studies.

Zasocitinib, Takeda's once-daily investigational TYK2 inhibitor, presented concurrent phase 3 data from the LATITUDE PsO 3001 and 3002 trials at the same meeting. In those studies, 71.4% and 69.2% of zasocitinib-treated patients achieved sPGA 0/1 at week 16 versus 10.7% and 12.6% with placebo (

 <.001), with PASI 75 responses observed as early as week 4 and more than 90% of week 40 responders maintaining response through week 60. Also arriving just before AAD, icotrokinra received FDA approval on March 18, 2026 as the first targeted oral peptide to precisely block the IL-23 receptor, with approval based on the phase 3 ICONIC program in approximately 2,500 patients. In the ICONIC-ADVANCE head-to-head studies, approximately 70% of patients achieved IGA 0/1 and 55% achieved PASI 90 at week 16, with icotrokinra demonstrating superiority over deucravacitinib at weeks 16 and 24.

Blauvelt placed these 3 agents in direct relation to one another, noting that the best IL-23 and IL-17 biologics likely still represent the ceiling for skin clearance. For patients prioritizing maximum efficacy, he would continue to favor those agents; however, for the many patients who prefer oral therapy and the many clinicians who remain reluctant to prescribe biologics, he characterized icotrokinra, envudeucitinib, and zasocitinib as agents that will move immediately to the top of the oral treatment hierarchy. He noted that dosing may be an early point of practical differentiation — zasocitinib and icotrokinra are once daily, while envudeucitinib is currently dosed twice daily, though Alumis has indicated plans to develop an extended-release once-daily formulation. He also raised the possibility that performance in psoriatic arthritis could ultimately drive prescribing choices among these agents if data reveal meaningful differences in joint outcomes. An NDA submission for envudeucitinib is planned for the second half of 2026.

Blauvelt’s disclosures include Abbvie, Almirall, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, Eli Lilly, Incyte, Janssen, LEO Pharma, Lipidio Pharma, Novartis, Oruka Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, Takeda, and UCB.

Blauvelt A, Sofen H, Armstrong A, et al. Envudeucitinib (ESK-001) in moderate-to-severe plaque psoriasis: 24-week results from the randomized, double-blind, active comparator- and placebo-controlled, phase 3 ONWARD1 and 2 studies. Presented at: AAD Annual Meeting; Denver, Colorado; March 27-31, 2026.

Alumis Inc. Alumis' envudeucitinib delivers early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two phase 3 trials, underscoring its potential as a leading oral therapy for plaque psoriasis. Press release. March 28, 2026. Accessed March 28, 2026. 

https://investors.alumis.com/news-releases/news-release-details/alumis-envudeucitinib-delivers-early-and-robust-improvements

Gooderham M, et al. Once-daily oral zasocitinib demonstrates rapid and reproducible skin clearance with a consistent safety profile in moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002). Presented at: AAD Annual Meeting; Denver, Colorado; March 27-31, 2026.

Johnson & Johnson. FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide. Press release. March 18, 2026. Accessed March 28, 2026. 

https://www.investor.jnj.com/investor-news/news-details/2026/FDA-approval-of-ICOTYDE-icotrokinra-ushers-in-new-era-for-first-line-systemic-treatment-of-plaque-psoriasis-with-a-targeted-oral-peptide/default.aspx

Phase 3 ONWARD data for the investigational TYK2 inhibitor envudeucitinib join a rapidly crowding oral psoriasis space.


Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Risk-Based Management in Hypercortisolism

In the final episode, ‘Risk-Based Management in Hypercortisolism,’ the panelists explored how to approach hypercortisolism management in the absence of widely accessible, targeted therapies, emphasizing a risk-based treatment paradigm. The panelists draw a parallel to lipoprotein(a), highlighting hypercortisolism as a prevalent and clinically meaningful risk factor that may not yet have straightforward therapeutic options for all patients. In this context, the expert faculty underscore the importance of aggressive optimization of modifiable cardiovascular and metabolic risk factors.

The discussion reinforces that hypercortisolism contributes broadly to systemic disease, affecting blood pressure, glucose metabolism, bone health, and cardiovascular outcomes. As such, clinicians should intensify management of hypertension, diabetes, dyslipidemia, and lifestyle factors to mitigate overall risk. Panelists note that while controlling these comorbidities may not fully eliminate the impact of cortisol excess, it can significantly improve patient outcomes while the field advances toward more targeted therapies.

The expert faculty also emphasize the concept of hypercortisolism as a continuum, suggesting that future treatment strategies may expand beyond overt disease to include earlier or milder forms. Finally, the panel highlights the practical implications of recent evidence, encouraging clinicians to adopt routine screening in high-risk populations and to integrate hypercortisolism into broader risk assessment and management frameworks.

Thank you for watching this peer exchange series on hypercortisolism. Please subscribe to our newsletter for information on upcoming video series.

In the final episode, ‘Risk-Based Management in Hypercortisolism,’ the panelists explored how to approach hypercortisolism management in the absence of widely accessible, targeted therapies, emphasizing a risk-based treatment paradigm. 

Video Series

In ‘Emerging Therapies in Hypercortisolism,’ our panel explores the evolving therapeutic landscape for hypercortisolism and the future direction of treatment development.

Emerging Therapies in Hypercortisolism

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

March 2026 endocrinology updates include key FDA approvals, advances in diabetes and obesity therapies, and innovations in insulin delivery and rare disease care.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Type 2 Diabetes

7 Endocrinology Headlines You Missed in March 2026

In this episode, ‘Hypercortisolism and Cardiovascular Risk Management,’ the panelists explore the broader implications of hypercortisolism on cardiovascular risk and the role of cardiologists in comprehensive patient management.

Hypercortisolism and Cardiovascular Risk Management

This episode, titled ‘Hypercortisolism Treatment and Care Pathways,’ features panelists discussing the management of hypercortisolism following diagnosis, with a focus on the roles of cardiologists and endocrinologists in coordinating care. 

Hypercortisolism Treatment and Care Pathways

In ‘Hypertension Management in Hypercortisolism,’our panel explores the clinical implications of emerging data on hypercortisolism and outline a forward-looking approach to hypertension management.

Hypertension Management in Hypercortisolism

In this episode, ‘Hypercortisolism and Guideline Implications,’ the panelists explore the implications of emerging hypercortisolism data for clinical guidelines and routine cardiovascular practice.

Hypercortisolism and Guideline Implications

This episode, titled ‘Recognizing Hypercortisolism in Cardiology,’ features panelists discuss the clinical implications of emerging hypercortisolism data for cardiologists and how these findings should influence everyday practice. 

Recognizing Hypercortisolism in Cardiology

In ‘Hypercortisolism Hidden in Resistant Hypertension,’ our panel explored the design, findings, and clinical implications of the MOMENTUM study, a large, multicenter trial evaluating the prevalence of hypercortisolism in patients with resistant hypertension.

Hypercortisolism Hidden in Resistant Hypertension

In this episode, ‘Hypercortisolism and Difficult to Control Diabetes,’ the panelists explore the relationship between hypercortisolism and difficult-to-control diabetes, highlighting the role of excess cortisol as a key driver of metabolic dysfunction.

Hypercortisolism and Difficult to Control Diabetes

This episode, titled ‘Hypercortisolism in Resistant Diabetes and Cardiometabolic Disease,’ features panelists expanding the discussion of hypercortisolism beyond hypertension to include patients with poorly controlled or “resistant” diabetes, highlighting another high-risk population where cortisol excess may be underrecognized. 

Latest News

Are We Overlooking Long-Term Risks in IBS Management? New 20-Year Safety Data, With Ali Rezaie, MD

Q1 2026 Recap: Cardiology News and Updates

Gaps in Home Dialysis Access Persist Globally, With Simon Davies, MD

How Envudeucitinib May Fit Into the Evolving Oral Psoriasis Landscape, With Andrew Blauvelt, MD, MBA

Risk-Based Management in Hypercortisolism